<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01308190</url>
  </required_header>
  <id_info>
    <org_study_id>TAU-TEM-2009-01</org_study_id>
    <nct_id>NCT01308190</nct_id>
  </id_info>
  <brief_title>Preoperative Chemoradiotherapy and Transanal Endoscopic Microsurgery Versus Total Mesorectal Excision in T2-T3s N0, M0 Rectal Cancer</brief_title>
  <official_title>Prospective Randomized Clinical Trial for no Inferiority With Preoperative Chemoradiotherapy and Transanal Endoscopic Microsurgery (TEM) Versus Total Mesorectal Excision in T2-T3s N0, M0 Rectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Corporacion Parc Tauli</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fundación Olga Torres</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Corporacion Parc Tauli</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The standard treatment of rectal adenocarcinoma is total mesorectal excision (TME). The
      technique involves a low anterior rectal or colo-anal resection, very often associated with a
      protective stoma or abdominal-perineal resection with permanent colostomy. Transanal
      endoscopic microsurgery (TEM) allows access to tumors up to 20 cm from the anal margin, with
      minimal postoperative morbidity and mortality. Recent studies of T1 rectal adenocarcinomas
      consider TEM to be the technique of choice. However the treatment of T2 rectal cancers
      remains controversial. Chemotherapy and radiotherapy (CT/RT) has achieved a concomitant
      reduction in local recurrence and an increase in survival.

      Hypothesis: Patients with rectal adenocarcinoma less than 10 cm from the anal margin and up
      to 4 cm in size, staged after endorectal ultrasound and MRI as T2 or superficial T3
      N0-M0-N0-M0, who underwent surgery after preoperative local chemoradiotherapy (TEM), achieve
      effective results in terms of local recurrence similar to radical surgery (TME).

      OBJECTIVES:

      Primary: To compare the results of local recurrence at 2 years in patients treated with
      preoperative chemoradiotherapy and TEM and in patients treated with conventional radical
      surgery (TME).

      Secondary: To analyse the 3-year survival results in patients treated with CT/RT.

      Methodology: Multicenter clinical trial in a calculated sample of 173 patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2010</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Local recurrence</measure>
    <time_frame>2 years</time_frame>
    <description>To analyse the results for local recurrence after 2 years in patients treated with preoperative chemoradiotherapy and TEO, with patients treated with conventional radical surgery (TME).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">173</enrollment>
  <condition>Rectal Cancer</condition>
  <arm_group>
    <arm_group_label>Chemoradiotherapy+TEM</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Preoperative chemotherapy: capecitabine 825 mg/m2 every 12 hours orally, plus Radiotherapy (50.4 Gy). After 6-8 weeks, transanal endoscopic microsurgery (TEM)is done</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Total Mesorectal Excision</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Standard surgical treatment of T2 , T3s, N0, M0 rectal cancer</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine (Xeloda)</intervention_name>
    <description>Capecitabine 825 mg/m2 every 12 hours orally on days of radiotherapy</description>
    <arm_group_label>Chemoradiotherapy+TEM</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>50.4 Gy</intervention_name>
    <description>Radiotherapy was administered in daily fractions of 1.8 Gy 5 days a week according to standard schema. The total dose is 45 Gy plus a boost of 5.4 Gy to the tumor area</description>
    <arm_group_label>Chemoradiotherapy+TEM</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Transanal Endoscopic Microsurgery</intervention_name>
    <description>6-8 weeks after Chemoradiotherapy</description>
    <arm_group_label>Chemoradiotherapy+TEM</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Total Mesorectal Excision</intervention_name>
    <description>Standard surgical treatment of T2 , T3s, N0, M0 rectal cancer. Early after diagnosis</description>
    <arm_group_label>Total Mesorectal Excision</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Rectal adenocarcinomas located 10 cm or less from the inferior anal verge measured
             using a rigid rectoscope at the time of the EUS.

          2. Preoperative staging by EUS and pelvic MRI of T2 or T3 superficial, N0. In case of
             disparity, the higher staging is considered as the definitive diagnosis.

          3. Tumours equal to or less than 4 cm of diameter maximum measured using colonoscopy, EUS
             or MRI. We use the highest score on both scores.

          4. ASA score III or less.

          5. Absence of distance metastasis as shown on abdominal CT.

        Exclusion Criteria:

          1. Preoperative staging by EUS or pelvic MRI of T1, deep T3, T4 or N1.

          2. Presence of distance metastasis.

          3. Synchrony with other colorectal adenocarcinomas.

          4. Undifferentiated rectal adenocarcinomas or with presence of poor prognosis factors in
             preoperative biopsy.

          5. Patients with intolerance of preoperative chemotherapy or radiotherapy.

          6. Refusal to sign informed consent to enter the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Xavier Serra-Aracil, MD</last_name>
    <phone>+34937231010</phone>
    <phone_ext>20009</phone_ext>
    <email>jserraa@tauli.cat</email>
  </overall_contact>
  <location>
    <facility>
      <name>Corporació Parc Taulí</name>
      <address>
        <city>Sabadell</city>
        <state>Barcelona</state>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xavier Serra-Aracil, MD</last_name>
      <phone>+34937231010</phone>
      <phone_ext>2009</phone_ext>
      <email>jserraa@tauli.cat</email>
    </contact>
    <investigator>
      <last_name>Xavier Serra-Aracil, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jordi Bombardo-Juncà, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carles Pericay Pijaume, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Serra Aracil X, Bombardó Juncá J, Mora López L, Alcantara Moral M, Ayguavives Garnica I, Darnell Marti A, Casalots Casado A, Pericay Pijaume C, Campo Fernández de Los Ríos R, Navarro Soto S. [Site of local surgery in adenocarcinoma of the rectum T2N0M0]. Cir Esp. 2009 Feb;85(2):103-9. doi: 10.1016/j.ciresp.2008.09.007. Epub 2009 Feb 5. Spanish.</citation>
    <PMID>19231466</PMID>
  </reference>
  <reference>
    <citation>Serra-Aracil X, Vallverdú H, Bombardó-Junca J, Pericay-Pijaume C, Urgellés-Bosch J, Navarro-Soto S. Long-term follow-up of local rectal cancer surgery by transanal endoscopic microsurgery. World J Surg. 2008 Jun;32(6):1162-7. doi: 10.1007/s00268-008-9512-1.</citation>
    <PMID>18338206</PMID>
  </reference>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 3, 2011</study_first_submitted>
  <study_first_submitted_qc>March 3, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 4, 2011</study_first_posted>
  <last_update_submitted>September 9, 2015</last_update_submitted>
  <last_update_submitted_qc>September 9, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 10, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Corporacion Parc Tauli</investigator_affiliation>
    <investigator_full_name>Xavier Serra-Aracil</investigator_full_name>
    <investigator_title>Medical Doctor</investigator_title>
  </responsible_party>
  <keyword>Preoperative chemoradiotherapy</keyword>
  <keyword>Transanal endoscopic microsurgery</keyword>
  <keyword>Rectal Cancer</keyword>
  <keyword>T2-T3s-N0</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

